PMCB PharmaCyte Biotech, Inc.: institutional ownership and insider trading
30 funds reported holding $707K of PharmaCyte Biotech, Inc. in their latest 13F filings; in Q2 2026 funds net sold $215K, with 2 new positions and 5 funds selling out; over the last 12 months insiders bought $129K and sold $0 on the open market; over its last four quarters it reported revenue of $0 and net income of −$16.1M.
PMCB revenue and earnings
- Quarter ended Jul 31, 2026: revenue $0, net income −$5.08M, EPS -0.54
- Quarter ended Apr 30, 2026: revenue $0, net income −$4.39M, EPS -0.13
- Quarter ended Jan 31, 2026: revenue $0, net income $747K, EPS -0.17
- Quarter ended Oct 31, 2025: revenue $0, net income −$7.42M, EPS -1.24
Famous investors holding PMCB
- Ken Griffin (Citadel Advisors): $285K, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $29.3K, 0.0% of the portfolio
Largest institutional holders of PMCB
- CITADEL ADVISORS LLC — $285K
- GEODE CAPITAL MANAGEMENT, LLC — $95.7K
- VANGUARD GROUP INC — $54.2K
- VANGUARD CAPITAL MANAGEMENT LLC — $43.7K
- SUSQUEHANNA INTERNATIONAL GROUP, LLP — $34.5K
- RENAISSANCE TECHNOLOGIES LLC — $29.3K
- XTX Topco Ltd — $26.3K
- NORTHERN TRUST CORP (NTRS, NTRSO) — $25.1K
- JANE STREET GROUP, LLC — $23.1K
- Schonfeld Strategic Advisors LLC — $20.7K
Recent PMCB insider trades
- Jan 7, 2026: Silverman Joshua bought 100,000 shares ($80.3K)
- Jan 7, 2026: Schechter Jonathan bought 60,000 shares ($48.2K)
5%+ owners
- Ayrton Capital LLC: 9.9% (Schedule 13G/A, filed Feb 13, 2025)
Who owns the most PMCB stock?
The largest institutional holders of PharmaCyte Biotech, Inc. in the latest 13F filings are CITADEL ADVISORS LLC ($285K), GEODE CAPITAL MANAGEMENT, LLC ($95.7K), VANGUARD GROUP INC ($54.2K).
Are insiders buying or selling PMCB?
Over the last 12 months insiders bought $129K and sold $0 of PharmaCyte Biotech, Inc. stock on the open market (SEC Form 4).
Which famous investors own PMCB?
Ken Griffin, Renaissance Technologies.
What was PMCB's revenue last quarter?
PharmaCyte Biotech, Inc. reported revenue of $0 for the quarter ended July 31, 2026, with net income of −$5.08M.